 "coronavirus, drugs, medicine, pharma, vaccine, research")
AstraZeneca Plc’s Covid-19 antibody cocktail was found to be 77% effective in preventing symptomatic Covid-19 in high-risk people in a key trial that could expand the range of drugs available to vulnerable groups.
Results from Astra’s study found no one in the trial who received the cocktail contracted severe Covid-19 or died in relation to the disease, the company said in a statement Friday. The trial of 5,197 participants, which started in November, was looking at whether the drug could prevent infection in at-risk groups and took place in the US, UK, Belgium, France and Spain.
The outcome will be a
